» Articles » PMID: 22184734

The Number of Women Who Would Need to Be Screened Regularly by Mammography to Prevent One Death from Breast Cancer

Overview
Journal J Med Screen
Specialty Public Health
Date 2011 Dec 21
PMID 22184734
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer depends strongly on several factors, including the age at which regular screening starts, the period over which it continues, and the duration of follow-up after screening. Furthermore, more women would need to be INVITED for screening than would need to be SCREENED to prevent one death, since not all women invited attend for screening or are screened regularly. Failure to consider these important factors accounts for many of the major discrepancies between different published estimates. The randomised evidence indicates that, in high income countries, around one breast cancer death would be prevented in the long term for every 400 women aged 50-70 years regularly screened over a ten-year period.

Citing Articles

Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.

Hu P, Prorok P, Katki H J Natl Cancer Inst. 2024; 117(2):303-311.

PMID: 39383209 PMC: 11807432. DOI: 10.1093/jnci/djae247.


Change in effectiveness of mammography screening with decreasing breast cancer mortality: a population-based study.

Christiansen S, Autier P, Stovring H Eur J Public Health. 2022; 32(4):630-635.

PMID: 35732293 PMC: 9341840. DOI: 10.1093/eurpub/ckac047.


National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017.

Bosetti C, Traini E, Alam T, Allen C, Carreras G, Compton K Sci Rep. 2020; 10(1):22099.

PMID: 33328623 PMC: 7744506. DOI: 10.1038/s41598-020-79176-3.


A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttamies A Eur J Epidemiol. 2017; 32(6):521-527.

PMID: 28762124 DOI: 10.1007/s10654-017-0292-5.


An Enhanced Shared Decision Making Model to Address Willingness and Ability to Undergo Lung Cancer Screening and Follow-Up Treatment in Minority Underserved Populations.

Erkmen C, Mitchell M, Randhawa S, Sferra S, Kim R, DiSesa V J Community Health. 2017; 43(1):27-32.

PMID: 28612174 DOI: 10.1007/s10900-017-0383-y.


References
1.
. Screening for breast cancer in England: past and future. J Med Screen. 2006; 13(2):59-61. DOI: 10.1258/096914106777589678. View

2.
Nelson H, Tyne K, Naik A, Bougatsos C, Chan B, Humphrey L . Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(10):727-37, W237-42. PMC: 2972726. DOI: 10.7326/0003-4819-151-10-200911170-00009. View

3.
Tabar L, Vitak B, Chen T, Yen A, Cohen A, Tot T . Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011; 260(3):658-63. DOI: 10.1148/radiol.11110469. View

4.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84. PMC: 3163848. DOI: 10.1016/S0140-6736(11)60993-8. View

5.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View